Global Recombinant Proteins Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Recombinant Proteins Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Recombinant protein refers to the protein obtained by applying the technology of recombinant DNA or recombinant RNA.

Market Overview:

The latest research study on the global Recombinant Proteins market finds that the global Recombinant Proteins market reached a value of USD 747.6 million in 2022. It’s expected that the market will achieve USD 1211.42 million by 2028, exhibiting a CAGR of 8.38% during the forecast period.

Market Drivers

The increasing demand for scientific research in the life sciences and the industrial market will promote the expansion of the overall scale of the biological scientific research reagent market. The importance of universities and scientific research institutions on the quantity and quality of scientific research results; industrial users' pursuit of increasing the output of medicines and related products; and the emphasis of medical and health institutions on epidemic prevention and monitoring have brought higher demands for biological scientific research reagents. And these factors promote the expansion of the market size of recombinant proteins.

Market Challenges

International Recombinant Proteins companies have taken a long time to develop and have gradually moved from a rapid growth period to a mature period. The development time of small Recombinant Proteins companies is relatively short, and the product types are yet to be enriched. In some product segments, they still have a strong dependence on international companies. The world-renowned manufacturers of recombinant proteins have strong competitiveness in most markets. In the future, with the support of various national policies, the recombinant proteins industry will gain further development, and the market competition will gradually become fierce.

Region Overview:

From 2022-2027, North America is estimated to witness robust growth prospects.

Company Overview:

Bio-Techne Corporation is one of the major players operating in the Recombinant Proteins market, holding a share of 11.48% in 2021.

Bio-Techne Corporation is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions.

Genscript Biotech Corporation is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.

Segmentation Overview:

Among different product types, Growth Factors segment is anticipated to contribute the largest market share in 2027.

Hormones purposefully affect the target tissue by binding to specific receptor proteins and elicit a specified action in the cellular target. When a hormone binds to the receptor protein, it results in the activation of a signal transduction mechanism.

Growth factor means a group of proteins that stimulate the growth of cell. Usually, it functions as hormone like regulatory signals, controlling the growth and differentiation of responsive cells. They are important for a variety of cellular processes.

Recombinant cytokines are generally designed to enhance immunity either by achieving generalized immunostimulant or stimulating specific immune cells. These proteins have not only improved treatment options for several diseases, but have also been associated with novel toxicities.

Recombinant plasma protein factor refers to obtaining plasma protein factor through genetic recombination technology. Compared with natural plasma protein factor, although the source is different, it has the same biological function.

Recombinant metabolic enzymes are produced using baculovirus-transfected insect cells and have high catalytic activity. Compared with the catalytic activity of the combined human liver microsomes (HLM) side by side, it can be used for many enzymes.

Application Overview:

By application, the Pharmaceutical & Biotechnology Companies segment occupied the biggest share from 2017 to 2022.

Recombinant proteins are commonly used to produce pharmaceutical products, protein-based polymers for drug delivery, antibodies and enzymes for disease treatment, protein scaffolds for tissue engineering, as well as for a myriad of other uses. Recombinant proteins are commonly used in Pharmaceutical & Biotechnology Companies.

Recombinant proteins are useful tools for understanding protein interactions. Protein interactions are fundamentally characterized as stable or transient, and play an important role in cellular processes. Edible recombinant protein, academic research institutions can study the interaction of protein with other proteins or peptides, enzymes, small molecules, lipids and nucleic acids.

Recombinant proteins can be expressed in bacteria, yeast, plants, insect cells, mammalian cells or transgenic animals. Recombinant proteins can be continuously monitored to determine virus exposure and evaluate vaccine efficacy, which plays an important role in controlling disease outbreaks. Recombinant proteins are also commonly used in diagnostic centers.

Key Companies in the global Recombinant Proteins market covered in Chapter 3:

Laurus Bio
Acrobiosystems
RayBiotech, Inc.
Miltenyi Biotec
Merck KGaA
Sino Biological Inc.
STEMCELL Technologies Inc
Peprotech, Inc.
Abcam plc
ProSpec-Tany TechnoGene Ltd.
Aviva Systems Biology Corporation
Cellgenix GmbH
Biolegend
Bio-Techne Corporation
BPS Bioscience, Inc.
Proteintech Group, Inc.
Thermo Fisher Scientific, Inc.
Enzo Life Sciences, Inc.
Bio-Rad Laboratories, Inc.
Genscript Biotech Corporation

In Chapter 4 and Chapter 14.2, on the basis of types, the Recombinant Proteins market from 2018 to 2029 is primarily split into:

Hormones
Growth Factors
Cytokines
Plasma Protein Factor
Recombinant Metabolic Enzymes
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Recombinant Proteins market from 2018 to 2029 covers:

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Diagnostic Centres
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)